Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback